Remdesivir and COVID-19

Lancet. 2020 Oct 3;396(10256):953-954. doi: 10.1016/S0140-6736(20)32019-5.

¹ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China.
² Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China.
³ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China; Hunan Key Laboratory of Precise Diagnosis and Treatment of Gastrointestinal Tumor, Changsha, China. Electronic address: yinjiye@csu.edu.cn.

No abstract available

Publication types